
5.21.074

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	July 1, 2016
Subject:	Gleevec	Page:	1 of 7

Last Review Date: March 6, 2026

Gleevec

Description

Gleevec (imatinib mesylate), Imkeldi (imatinib)

Background

Gleevec (imatinib mesylate) and Imkeldi (imatinib) are anticancer medicines that work as an inhibitor of BCR-ABL tyrosine kinase enzyme. This enzyme is the abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia. Inhibition of this enzyme by Gleevec and Imkeldi inhibit proliferation and induce apoptosis in BCR-ABL positive cell lines and fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Gleevec and Imkeldi also act to inhibit tyrosine kinase for platelet-derived growth factor, stem-cell factor, c-Kit, and cellular events mediated by platelet-derived growth factor and stem-cell factor (1-2).

Regulatory Status

FDA-approved indications: Gleevec and Imkeldi are tyrosine kinase inhibitors indicated for: (1-2)

1. Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase
2. Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy
3. Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
4. Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	July 1, 2016
Subject:	Gleevec	Page:	2 of 7

5. Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements
6. Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown
7. Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR α fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1- PDGFR α fusion kinase negative or unknown
8. Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)
9. Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)
10. Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST

Off-Label Uses: (3-5)

1. Treatment of patients with advanced phase CML (accelerated phase or blast phase)
2. Follow-up therapy for CML patients after hematopoietic stem cell transplant (HSCT)
3. Ph+ ALL/ Lymphoblastic lymphoma
4. Gastrointestinal Stromal tumor (GIST) (primary, preoperative, postoperative and continued treatment)
5. Dermatofibrosarcoma protuberans (DFSP)
6. Desmoid tumors
7. Pigmented villonodular synovitis / tenosynovial giant cell tumor (PVNS/TGCT)
8. Chordoma
9. C-Kit mutated melanoma

Gleevec and Imkeldi should be used with caution in patients at increased risk for cardiac failure, patients with high eosinophil levels (e.g., HES, MDS/MPD and ASM), thyroidectomy patients, pregnant women, and children. Reports of edema, severe fluid retention, cytopenias, severe congestive heart failure, cardiogenic shock, left ventricular dysfunction, severe hepatotoxicity (including fatalities), hypothyroidism, fetal harm, growth retardation, and motor vehicle accidents have occurred in patients on Gleevec and Imkeldi (1-2).

Patients should be weighed regularly, and unexpected rapid weight gain should be managed by drug interruption and diuretics. CBC testing should also be performed weekly the first month, biweekly the second month, and periodically thereafter. Liver function should be assessed before initiation and monthly thereafter or as clinically indicated. TSH levels in thyroidectomy

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	July 1, 2016
Subject:	Gleevec	Page:	3 of 7

patients and growth rates in children should be closely monitored. Patients should also be cautioned about driving a car or operating machinery while on Gleevec and Imkeldi (1-2).

The safety and effectiveness of Gleevec and Imkeldi have not been established in children less than 1 year of age (1-2).

Related policies

Bosulif, Blinicyto, Erwinaze, Iclusig, Marqibo, Scemblix, Sprycel, Stivarga, Synribo, Tassigna

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Gleevec and Imkeldi may be considered **medically necessary** if the conditions indicated below are met.

Gleevec and Imkeldi may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 1 year of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Chronic myeloid leukemia (CML)
2. Chronic myeloid leukemia (CML) post hematopoietic stem cell transplant (HSCT)
3. Ph+ Acute lymphoblastic leukemia (ALL)

AND ALL of the following for 1 thru 3:

- a. Confirmed by molecular testing by the detection of the Ph chromosome or BCR-ABL gene prior to initiation of therapy
- b. If the patient has had prior therapy with a TKI then **ONE** of the following requirements must be met:
 - i. Member experienced resistance to prior therapy with TKI

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	July 1, 2016
Subject:	Gleevec	Page:	4 of 7

- 1) Results from mutational testing are negative for the T315I mutation
 - ii. Member experienced toxicity or intolerance to prior therapy with a TKI
4. Myelodysplastic/myeloproliferative diseases (MDS/MPD)
 - a. Confirmed with PDGFR (platelet-derived growth factor receptor) gene re-arrangement
5. Aggressive systemic mastocytosis (ASM) with **ONE** of the following mutations:
 - a. Confirmed without the D816V c-Kit mutation by genetic test
 - b. Confirmed with c-Kit mutational status unknown
6. Gastrointestinal stromal tumors (GIST)
7. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
8. Dermatofibrosarcoma protuberans (DFSP)
9. Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)
10. Melanoma
 - a. Confirmed c-Kit mutation-positive

AND the following for **ALL** indications:

- a. **Brand Gleevec only:** Inadequate treatment response, intolerance, or contraindication to generic Gleevec: imatinib

Prior – Approval *Renewal* Requirements

Age 1 year of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Chronic myeloid leukemia (CML)
2. Chronic myeloid leukemia (CML) post hematopoietic stem cell transplant (HSCT)
3. Ph+ Acute lymphoblastic leukemia (ALL)
4. Myelodysplastic / myeloproliferative diseases (MDS/MPD)
5. Aggressive systemic mastocytosis (ASM)
6. Gastrointestinal stromal tumors (GIST)
7. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
8. Dermatofibrosarcoma protuberans (DFSP)
9. Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	July 1, 2016
Subject:	Gleevec	Page:	5 of 7

10. Melanoma

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 800 mg per day

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Gleevec and Imkeldi are tyrosine kinase inhibitors that target BCR-ABL, platelet-derived growth factor, stem-cell factor, c-Kit, and cellular events mediated by platelet-derived growth factor (PDGFR) and stem-cell factor. Gleevec and Imkeldi inhibit proliferation and induce apoptosis in these cell lines and can be used to treat diseases characterized by these particular cell lines growing out of control. The safety and effectiveness of Gleevec and Imkeldi have not been established in children less than 1 year of age (1-2).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Gleevec and Imkeldi while maintaining optimal therapeutic outcomes.

References

1. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; December 2025.
2. Imkeldi [package insert]. Cambridge, MA: Shorla Oncology Inc.; November 2024.
3. NCCN Drugs & Biologics Compendium[®] Imatinib 2026. National Comprehensive Cancer Network, Inc. Accessed on January 15, 2026.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	July 1, 2016
Subject:	Gleevec	Page:	6 of 7

- NCCN Clinical Practice Guidelines in Oncology[®] Chronic Myeloid Leukemia (Version 1.2026). National Comprehensive Cancer Network, Inc. July 2025. Accessed on January 15, 2026.
- NCCN Clinical Practice Guidelines in Oncology[®] Acute Lymphoblastic Leukemia (Version 2.2025). National Comprehensive Cancer Network, Inc. June 2025. Accessed on January 15, 2026.

Policy History

Date	Action
July 2016	Addition to PA
December 2016	Annual review Removal of first line treatment from CML and removal of confirmation the D816V c-Kit mutation from the renewal section
March 2017	Addition of the “genetic test” to confirmed without the D816V c-Kit mutation Annual editorial review Addition of no dual therapy with another tyrosine kinase inhibitor
November 2017	Addition of quantity limits
March 2018	Annual editorial review Addition of “If the patient has had prior therapy with a TKI then ONE of the following requirements must be met: member experienced resistance to prior therapy with TKI and results from mutational testing are negative for the T315I mutation or member experienced toxicity or intolerance to prior therapy with a TKI to these indications CML, CML post HSCT and Ph+ ALL
June 2019	Annual review and reference update
December 2019	Annual review. Addition of requirement to trial preferred product for initiation of therapy and removed no dual therapy with another TKI requirement
March 2020	Updated requirement of trial preferred product for CML
June 2020	Annual review and reference update
June 2021	Annual review and reference update
March 2022	Annual review and reference update
December 2022	Annual review and reference update. Changed policy number to 5.21.074
June 2023	Annual review and reference update
December 2023	Annual review and reference update
June 2024	Annual editorial review and reference update. Changed quantity limit to 800 mg per day
December 2024	Annual review and reference update. Changed Medex requirement to t/f imatinib only for all indications
March 2025	Annual editorial review and reference update. Addition of Imkeldi to policy

5.21.074

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	July 1, 2016
Subject:	Gleevec	Page:	7 of 7

June 2025	Annual review and reference update
December 2025	Annual review and reference update. Removed MedEx requirement and switched to t/f
March 2026	Annual review and reference update

[Keywords](#)

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.